Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Campbell on the Impact of the COVID-19 Pandemic in RCC

January 8th 2021

Matthew T. Campbell, MD, MS, discusses the impact of the coronavirus disease 2019 pandemic in renal cell carcinoma.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology

January 8th 2021

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.

Supportive Care for mRCC: Current Practices

January 8th 2021

Drs Robert Alter and Robert Motzer discuss the rationale and use of surgery as supportive care to treat appropriate patients with metastatic renal cell carcinoma.

Treatment Planning and Risk Assessment in mRCC

January 8th 2021

The importance of risk assessment when selecting frontline therapy to treat advanced renal cell carcinoma and factors to consider when talking with patients about goals of therapy.

Dr. Grigg on the Results of the CheckMate-214 Trial in RCC

January 7th 2021

Claud M. Grigg, Jr., MD, discusses the results of the CheckMate-214 trial in renal cell carcinoma.

Eganelisib/Nivolumab Elicits Promising Responses, PFS Benefit in Metastatic Urothelial Cancer

January 7th 2021

January 7th, 2021 - The addition of eganelisib to nivolumab was found to elicit encouraging responses and improve progression-free survival compared with single-agent nivolumab in patients with platinum-refractory, immunotherapy-naïve, advanced, metastatic urothelial cancer.

Dr. McGregor on the Focus of Future Research Efforts in RCC

January 7th 2021

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Dr. Gupta on Developing Biomarkers of Lack of Response in Urothelial Carcinoma

January 5th 2021

Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.

Telaglenastat Plus Cabozantinib Fails to Improve PFS in Advanced or Metastatic RCC

January 4th 2021

The combination of telaglenastat plus cabozantinib failed to result in a significant improvement in progression-free survival in patients with advanced or metastatic renal cell carcinoma.

Expert Compares Open vs Robotic Radical Cystectomy Approaches in Muscle Invasive Bladder Cancer

January 2nd 2021

Bryon Lee, MD, PhD, discusses recent advances in surgical technique, approach, and perioperative care have made radical cystectomy significantly less morbid for patients with muscle invasive bladder cancer.

Mian Makes Sense of Multidisciplinary Bladder Preservation Approaches

December 31st 2020

Omar Mian, MD, PhD, discusses selective bladder preservation in patients with muscle-invasive bladder cancer, biomarkers of response, and the utilization of hypofractionated radiation vs traditional approaches in this population.

Despite Efforts Made With Immunotherapy in Metastatic Urothelial Cancer, Chemotherapy Remains King in Frontline

December 30th 2020

Shilpa Gupta, MD, discusses ongoing research with immunotherapy in bladder cancer, where research efforts should focus with regard to biomarkers, and other emerging agents that might move the needle forward.

mRCC Risk Assessment and Treatment Options

December 23rd 2020

Preferred treatment regimens that incorporate novel therapies used to treat patients with metastatic renal cell carcinoma based on risk status.

Risk Stratification in Renal Cell Carcinoma

December 23rd 2020

A historical overview regarding the development of parameters used to help stratify risk in patients with renal cell carcinoma and the relevance of current models in the context of selecting systemic therapy to treat appropriate patients.

Dr. Powles on the Rationale to Evaluate ctDNA in High-Risk Muscle-Invasive Bladder Cancer

December 22nd 2020

Thomas Powles, MBBS, MRCP, MD, discusses the rationale to evaluate circulating tumor DNA in high-risk muscle-invasive bladder cancer.

N-803 Plus BCG Elicits 72% CR in BCG-Unresponsive, High-Grade Non-Muscle Invasive Bladder Cancer

December 22nd 2020

December 22, 2020 — Intravesical Bacillus Calmette-Guerin in combination with N-803 was found to induce a complete response rate of 72% in patients with non-muscle invasive bladder cancer in high-risk carcinoma in situ disease, meeting the primary end point of the phase 2/3 QUILT 3.032 trial.

Multimodality Therapy Makes Waves in Bladder Cancer

December 21st 2020

Faculty from a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic share updates in the management of metastatic urothelial carcinoma, as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.

Newly Diagnosed RCC: Treatment Planning

December 18th 2020

Guidelines and recommendations by clinicians on treatment approaches for newly diagnosed renal cell carcinoma and regimens in the pipeline that may impact future treatment.

Supportive Care and Systemic Therapy for RCC

December 18th 2020

Advice to health care providers on when to refer patients for further assessment of potential renal cell carcinoma and insight on the types of diagnostic tests used to help confirm a diagnosis in the era of molecular testing.